0.2963
price down icon0.20%   -0.0006
after-market Dopo l'orario di chiusura: .28 -0.0163 -5.50%
loading
Precedente Chiudi:
$0.2969
Aprire:
$0.28
Volume 24 ore:
458.19K
Relative Volume:
0.22
Capitalizzazione di mercato:
$17.31M
Reddito:
$1.50M
Utile/perdita netta:
$-64.59M
Rapporto P/E:
-0.1774
EPS:
-1.67
Flusso di cassa netto:
$-55.17M
1 W Prestazione:
+5.78%
1M Prestazione:
-21.61%
6M Prestazione:
-89.69%
1 anno Prestazione:
-84.16%
Intervallo 1D:
Value
$0.271
$0.3195
Intervallo di 1 settimana:
Value
$0.2616
$0.3195
Portata 52W:
Value
$0.2223
$4.79

Leap Therapeutics Inc Stock (LPTX) Company Profile

Name
Nome
Leap Therapeutics Inc
Name
Telefono
617 252 4343
Name
Indirizzo
47 THORNDIKE STREET, CAMBRIDGE, MA
Name
Dipendente
52
Name
Cinguettio
@LeapTherapeutic
Name
Prossima data di guadagno
2024-11-11
Name
Ultimi documenti SEC
Name
LPTX's Discussions on Twitter

Confronta LPTX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
LPTX
Leap Therapeutics Inc
0.2963 17.31M 1.50M -64.59M -55.17M -1.67
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

Leap Therapeutics Inc Stock (LPTX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-01-29 Downgrade H.C. Wainwright Buy → Neutral
2025-01-29 Downgrade Robert W. Baird Outperform → Neutral
2024-06-28 Iniziato Rodman & Renshaw Buy
2021-10-04 Iniziato Mizuho Buy
2021-06-04 Ripresa Robert W. Baird Outperform
2020-06-29 Iniziato Piper Sandler Overweight
2020-02-11 Iniziato Robert W. Baird Outperform
2019-11-15 Downgrade Raymond James Outperform → Mkt Perform
2019-09-13 Ripresa Raymond James Outperform
2017-03-07 Iniziato Ladenburg Thalmann Buy
Mostra tutto

Leap Therapeutics Inc Borsa (LPTX) Ultime notizie

pulisher
Jun 18, 2025

2025 R&D layoffs tracker hits 132,075 as Amazon CEO signals AI will cut more jobs - R&D World

Jun 18, 2025
pulisher
Jun 16, 2025

Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace

Jun 16, 2025
pulisher
Jun 12, 2025

Fierce Biotech Layoff Tracker 2025: ADC Tx lets go of 30% of workers; Vertex sheds 125 staffers - Fierce Biotech

Jun 12, 2025
pulisher
Jun 10, 2025

Ligachem inks two mystery ADC deals with CSPC subsidiary Novarock - BioWorld MedTech

Jun 10, 2025
pulisher
Jun 09, 2025

HER2+ Gastric Cancer (including GEJ) Market to Increase at a Remarkable Growth Rate of 13% During the Study Period (2020-2034) | DelveInsight - The Malaysian Reserve

Jun 09, 2025
pulisher
Jun 09, 2025

Prostate Cancer Treatment Market Size in the 7MM was ~USD 12,300 million in 2023 and is expected to show positive growth by 2034, estimates DelveInsight - Barchart.com

Jun 09, 2025
pulisher
Jun 08, 2025

Jane Street Group LLC Decreases Holdings in Dakota Gold Corp. (NYSE:DC) - Defense World

Jun 08, 2025
pulisher
Jun 08, 2025

Jane Street Group LLC Purchases New Position in Leap Therapeutics, Inc. (NASDAQ:LPTX) - Defense World

Jun 08, 2025
pulisher
May 28, 2025

Leap Therapeutics Reports Increased Q1 Losses - TipRanks

May 28, 2025
pulisher
May 21, 2025

Metastatic Colorectal Cancer Pipeline Appears Robust With 150+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - Barchart.com

May 21, 2025
pulisher
May 21, 2025

Finance Watch: Prime, Kyverna, Allogene And More Announce Job Cuts - insights.citeline.com

May 21, 2025
pulisher
May 20, 2025

CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Leap 225% Yet They're Still Not Telling The Full Story - simplywall.st

May 20, 2025
pulisher
May 17, 2025

HC Wainwright Issues Optimistic Outlook for LPTX Earnings - Defense World

May 17, 2025
pulisher
May 13, 2025

Metastatic Colorectal Cancer Clinical Trial Pipeline Accelerates as 150+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - GlobeNewswire

May 13, 2025
pulisher
May 13, 2025

Metastatic Colorectal Cancer Clinical Trial Pipeline Accelerates as 150+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.

May 13, 2025
pulisher
May 13, 2025

Cash-strapped Cambridge cancer biotech cuts 50% of its staff - NBC Boston

May 13, 2025
pulisher
May 13, 2025

Cash-strapped Cambridge cancer biotech halves workforce - The Business Journals

May 13, 2025
pulisher
May 13, 2025

Leap halves head count, narrows lead cancer drug's focus amid 'difficult market environment' - Fierce Biotech

May 13, 2025
pulisher
May 13, 2025

Leap Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 13, 2025
pulisher
May 13, 2025

Leap Therapeutics Q1 Net Income USD -15.435 Million - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Leap Therapeutics Reports First Quarter 2025 Financial Results | - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Leap Therapeutics Reports First Quarter 2025 Financial Results - Citizen Tribune

May 13, 2025
pulisher
May 13, 2025

Leap TherapeuticsAnnounces 50% Workforce Reduction In Strategic RestructuringSEC Filing - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Leap Therapeutics, Inc. (LPTX) Q1 Loss Beats Estimates - Nasdaq

May 13, 2025
pulisher
May 13, 2025

LEAP THERAPEUTICS, INC. SEC 10-Q Report - TradingView

May 13, 2025
pulisher
May 13, 2025

Leap Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 13, 2025
pulisher
May 12, 2025

Purple Biotech Appoints Shai Lankry as Chief Financial Officer - The Manila Times

May 12, 2025
pulisher
May 10, 2025

Leap Therapeutics (LPTX) Expected to Announce Quarterly Earnings on Monday - Defense World

May 10, 2025
pulisher
May 09, 2025

Leap Therapeutics Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView

May 09, 2025
pulisher
May 07, 2025

Closing Bell Recap: Leap Therapeutics Inc (LPTX) Ends at 0.34, Reflecting a -12.39 Downturn - DWinneX

May 07, 2025
pulisher
May 01, 2025

LPTX’s Market Whiplash: -85.46% YTD Decline, 37.04% Rise in 30 Days - investchronicle.com

May 01, 2025
pulisher
Apr 30, 2025

75,800 Shares in Leap Therapeutics, Inc. (NASDAQ:LPTX) Acquired by LPL Financial LLC - Defense World

Apr 30, 2025
pulisher
Apr 30, 2025

Enovix Corporation (NASDAQ: ENVX)’s Potential for Significant Price Increase in the Near Future - Marketing Sentinel

Apr 30, 2025
pulisher
Apr 29, 2025

Quarterly Snapshot: Quick and Current Ratios for Leap Therapeutics Inc (LPTX) - DWinneX

Apr 29, 2025
pulisher
Apr 25, 2025

Leap Therapeutics to Present Preclinical Data of FL-501, a Novel - GuruFocus

Apr 25, 2025
pulisher
Apr 25, 2025

Novel Cancer Cachexia Drug FL-501 Shows 3X Better Half-Life in Preclinical Data | LPTX Stock News - Stock Titan

Apr 25, 2025
pulisher
Apr 25, 2025

Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting - PR Newswire

Apr 25, 2025
pulisher
Apr 23, 2025

Metastatic Colorectal Cancer Market Poised for Expansion Across the 7MM During the Forecast Period (2025-2034) as Breakthrough Therapies Gain Traction | DelveInsight - PR Newswire

Apr 23, 2025
pulisher
Apr 15, 2025

Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatam - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer | LPTX Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Leading Oncologist Reveals Game-Changing Phase 2 Results for Advanced Colorectal Cancer Treatment - Stock Titan

Apr 15, 2025
pulisher
Apr 15, 2025

Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer - PR Newswire

Apr 15, 2025
pulisher
Apr 05, 2025

Leap Therapeutics stock hits 52-week low at $0.28 amid downturn - Investing.com Canada

Apr 05, 2025
pulisher
Apr 04, 2025

Leap Therapeutics stock hits 52-week low at $0.28 amid downturn By Investing.com - Investing.com South Africa

Apr 04, 2025
pulisher
Apr 03, 2025

BlossomHill Therapeutics to Present the Design and Discovery of BH-30643, the Company’s OMNI-EGFR™ Inhibitor, at the 2025 AACR Annual Meeting - Business Wire

Apr 03, 2025
pulisher
Mar 31, 2025

HC Wainwright Expects Reduced Earnings for Leap Therapeutics - Defense World

Mar 31, 2025
pulisher
Mar 29, 2025

Leap Therapeutics (NASDAQ:LPTX) Earns Neutral Rating from HC Wainwright - The AM Reporter

Mar 29, 2025
pulisher
Mar 29, 2025

HC Wainwright Reiterates Neutral Rating for Leap Therapeutics (NASDAQ:LPTX) - Defense World

Mar 29, 2025
pulisher
Mar 28, 2025

H.C. Wainwright maintains neutral on Leap Therapeutics stock By Investing.com - Investing.com Canada

Mar 28, 2025
pulisher
Mar 27, 2025

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

Mar 27, 2025

Leap Therapeutics Inc Azioni (LPTX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.74
price up icon 0.39%
$35.88
price down icon 0.42%
$21.20
price down icon 0.38%
$97.62
price down icon 3.00%
$107.51
price up icon 0.98%
biotechnology ONC
$245.16
price up icon 1.28%
Capitalizzazione:     |  Volume (24 ore):